landomycin e

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

landomycin E: structure given in first source; isolated from Streptomyces sp. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	53297398
CHEBI ID	81891
MeSH ID	M0293299

Synonyms (4)

Synonym
landomycin e
C18685
CHEBI:81891
Q27155649

Research Excerpts

Overview

Landomycin E (LE) is an angucycline antibiotic produced by Streptomyces globisporus.

Excerpt	Reference	Relevance
"Landomycin E (LE) is an angucycline antibiotic produced by Streptomyces globisporus. "	( Rapid generation of hydrogen peroxide contributes to the complex cell death induction by the angucycline antibiotic landomycin E. Berger, W; Downey, T; Heffeter, P; Herbacek, I; Jha, AK; Kril, IJ; Lehka, LV; Matselyukh, BP; Panchuk, RR; Rohr, J; Stoika, RS; Terenzi, A; van Schoonhoven, S, 2017)	2.11

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
oligosaccharide	A compound in which monosaccharide units are joined by glycosidic linkages. The term is commonly used to refer to a defined structure as opposed to a polymer of unspecified length or a homologous mixture. When the linkages are of other types the compounds are regarded as oligosaccharide analogues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (26)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	19 (73.08)	29.6817
2010's	7 (26.92)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	10.60 (24.57)
Research Supply Index	3.74 (2.92)
Research Growth Index	4.33 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (10.60)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (2.44%)	6.00%
Case Studies	1 (2.44%)	4.05%
Observational	0 (0.00%)	0.25%
Other	39 (95.12%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.15	1	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
streptomycin [no description available]	2.11	1	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
chrysomycin a chrysomycin A: Streptomyces arenae; differs only in sugar moiety from gilvocarcin V	3.17	1	glycoside
tetrangulol tetrangulol: structure in first source. tetrangulol : A member of the class of tetraphenes that is tetraphene-7,12-dione substituted by hydroxy groups at positions 1 and 8 and a methyl group at position 3.	2.07	1	p-quinones; phenols; tetraphenes	bacterial metabolite
ay 25545 ravidomycin: isolated from mycelium of Streptomyces ravidus; structure given in first source. ravidomycin : A C-glycosylated naphthoisochromene derivative obtained from Streptomyces ravidus; exhibits antibiotic and anticancer properties.	3.17	1	acetate ester; aromatic ether; C-glycosyl compound; naphthoisochromene; olefinic compound; phenols; tertiary amine	antimicrobial agent; antineoplastic agent; bacterial metabolite
glycosides [no description available]	3.55	2
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	4.06	4
landomycin a landomycin A: structure given in first source; isolated from Streptomyces sp.	4.54	7	oligosaccharide	metabolite
gilvocarcin v gilvocarcin V: from Actinomycete DO-38; structure given in first source	3.17	1
jadomycin a jadomycin A: the aglycone of jadomycin B; structure in first source. jadomycin A : A organic heteropentacyclic compound that is 1,2,8,13-tetrahydro-3aH-benzo[b][1,3]oxazolo[3,2-f]phenanthridine which carries oxo groups at positions 2, 8 and 13, methyl group at position 5, hydroxy groups at positions 7 and 12, and a (2R)-butan-2-yl group at position 1. It is a mixture of epimers at the hemiaminal carbon (position 3a).	3.17	1
nad NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.	2.07	1	organophosphate oxoanion	cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite
jadomycin b jadomycin B: structure given in first source; isolated from Streptomyces venezuelae. jadomycin B : A jadomycin that is jadomycin A in which the phenolic hydroxy group at position 12 has been converted to the corresponding 2,6-dideoxy-alpha-L-ribo-hexopyranoside, isolated from Streptomyces venezuelae. It exists as a diastereoisomeric mixture consisting of both 3aS and 3aR isomers.	3.17	1	glycoside; jadomycin; organic heteropentacyclic compound	antibacterial agent; antineoplastic agent; apoptosis inducer; Aurora kinase inhibitor; bacterial metabolite
landomycinone landomycinone: structure in first source	7.02	1
landomycin d landomycin D: structure in first source	2.72	3	anthraquinone	metabolite
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	3.17	1	benzenes; hydroxycoumarin; methyl ketone
transforming growth factor beta Transforming Growth Factor beta: A factor synthesized in a wide variety of tissues. It acts synergistically with TGF-alpha in inducing phenotypic transformation and can also act as a negative autocrine growth factor. TGF-beta has a potential role in embryonal development, cellular differentiation, hormone secretion, and immune function. TGF-beta is found mostly as homodimer forms of separate gene products TGF-beta1, TGF-beta2 or TGF-beta3. Heterodimers composed of TGF-beta1 and 2 (TGF-beta1.2) or of TGF-beta2 and 3 (TGF-beta2.3) have been isolated. The TGF-beta proteins are synthesized as precursor proteins.	7.02	1
chrysomycin b chrysomycin B: structure given in first source	3.17	1
kinamycin a kinamycin A: isolated from Streptomyces muragamaensis; RN in Chemline for Kinamycin B: 35303-13-0; RN for Kinamycin C: 35303-08-3; RN for Kinamycin D: 35303-14-1; RN given refers to parent cpd; structure	3.17	1	kinamycin
kinamycin f kinamycin F: isolated from Streptomyces murayamaensis; structure given in first source	3.17	1	kinamycin
angucyclinone angucyclinone: structure in first source	3.17	1

Condition	Relationship Strength	Studies
Leucocythaemia [description not available]	2.15	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.15	1
Benign Neoplasms [description not available]	2.99	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.99	1
Adenocarcinoma, Basal Cell [description not available]	2.02	1
Breast Cancer [description not available]	2.02	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.02	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.02	1

chemdatabank.com